Yahoo Finance | EN590 Commodities
EN590 Commodities GroupMarket Analysis 2026-07-08T15:04:48+00:00
We recently compiled a list of the10 Best Innovative Healthcare Stocks to Buy Now. Genmab A/S (NASDAQ:GMAB) is one of thebest healthcare stockson our list. TheFly reported on July 2 that H.C. Wainwright analyst Raghuram Selvaraju increased the price target on GMAB to $40 from $38 while reaffirming a Buy rating on the shares. The revision followed the company's announcement that the EPCORE DLBCL-4 trial achieved its primary endpoint. Based on the trial outcome, the firm raised its estimated likelihood of regulatory approval for Epkinly to 70% in the first-line setting and 95% in the second-line setting. In a major secondary development on July 6, Genmab A/S (NASDAQ:GMAB) announced that the European Commission approved marketing authorization for TEPKINLY in combination with lenalidomide and
About EN590 Commodities Group
25+ years in mineral exploration and extraction. 15+ years of global commodity trading. Based in New York, USA serving 75+ countries.